Ricolinostat, the first-in-class HDAC6 selective inhibitor, has demonstrated good toxicity profile in patients and preliminary evidence of anti-myeloma efficacy in combination with lenalidomide and dexamethasone [78]. The gene discussed is HDAC6; the disease is plasma cell myeloma.